Bristol-Myers Squibb | BMY - Gewinn Vor Steuern

Aktienkurs
57.59
Täglich Wechseln
-0.67 -1.15%
Monatlich
-3.58%
Jährlich
14.72%
Q2 Prognose
57.45




Gewinn Vor Steuern Veränderung Datum
AbbVie USD 2.67B 1.71B 2025-12
Abbott USD 2.39B 27M 2026-03
ALKERMES USD 100.74M 4.1M 2025-09
Amgen USD 3.92B 2.35B 2025-09
AstraZeneca USD 2.63B 615M 2025-12
Biogen USD -56M 613.3M 2025-12
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Coherus Biosciences USD -46.35M 90.86M 2025-12
Drreddys Laboratories INR 15.43B 1.96B 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
J&J USD 7.82B 2.86B 2026-03
Medtronic USD 2.1B 224M 2025-09
Merck USD 6.74B 22M 2025-09
Novartis USD 4.64B 445M 2025-12
Novo Nordisk DKK 33.8B 3.23B 2025-06
Perrigo USD 22.4M 19.2M 2025-09
Pfizer USD 3.33B 290M 2025-09
Phibro Animal Health USD 38.62M 1.26M 2025-12
Prestige Brands USD 69.13M 7.35M 2025-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 5.5B 2025-12
Sanofi EUR -1.16B 6.23B 2025-12
United Therapeutics USD 444M 6M 2025-12
Zoetis USD 887M 15M 2025-09